Immunex' Novantrone prostate cancer journal ads to begin in December.
Executive Summary
IMMUNEX NOVANTRONE PROSTATE CANCER JOURNAL ADS TO BEGIN IN DECEMBER following Nov. 13 supplemental approval of mitoxantrone injection for use in combination with corticosteroids as "initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer." FDA approved the additional oncologic indication one day before the application's (sNDA 19-297/S-014) Nov. 14 six-month user fee deadline.